Banque Cantonale Vaudoise’s Oramed Pharmaceuticals ORMP Stock Holding History

Banque Cantonale Vaudoise’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-20,000	Closed	-$130K	–	1225
2022 Q3	$130K	Hold	20,000	–	–	0.01%	822
2022 Q2	$92K	Hold	20,000	–	–	﹤0.01%	903
2022 Q1	$173K	Hold	20,000	–	–	0.01%	831
2021 Q4	$286K	Hold	20,000	–	–	0.01%	744
2021 Q3	$440K	Buy	+20,000	New	+$341K	0.02%	601

Other funds holding ORMP

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Banque Cantonale Vaudoise's ORMP Position: Q4 2022 in Review

Banque Cantonale Vaudoise sold out of Oramed Pharmaceuticals (ORMP) in Q4 2022, closing a stake of 20,000 shares — an estimated $130K sold.

Banque Cantonale Vaudoise first reported a position in ORMP in Q3 2021 and held it in 5 quarters. The position peaked at $440K in Q3 2021. 77 funds tracked by Wall St. Rank hold ORMP as of Q4 2022.

Banque Cantonale Vaudoise reported no remaining Oramed Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Banque Cantonale Vaudoise sold 20,000 Oramed Pharmaceuticals shares in Q4 2022, an estimated $130K.
Banque Cantonale Vaudoise first reported a position in Oramed Pharmaceuticals in Q3 2021 and held it in 5 quarters.
Banque Cantonale Vaudoise's Oramed Pharmaceuticals position peaked at $440K in Q3 2021.
77 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2022.

Based on Banque Cantonale Vaudoise's 13F filing for Q4 2022, filed 10 Feb 2023.